Rallybio Corp. (RLYB)

16.81 +0.05 (+0.30%) USD  |  NASDAQ  |  Aug 28, 16:00
16.84 +0.03 (+0.18%) After-Hours: 20:00
More

Rallybio Revenue Estimates for Next Fiscal Year

Revenue Estimates for Next Fiscal Year Chart

View Revenue Estimates for Next Fiscal Year for RLYB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Next Fiscal Year Chart
Start Trial

Historical Revenue Estimates for Next Fiscal Year Data

View and export this data back to 2023. Start Trial.
Date Value
March 02, 2026 --
November 14, 2025 --
November 10, 2025 --
November 06, 2025 --
September 25, 2025 --
September 03, 2025 --
August 11, 2025 --
August 07, 2025 --
July 08, 2025 --
June 12, 2025 --
May 13, 2025 --
May 08, 2025 --
April 14, 2025 --
March 14, 2025 --
December 02, 2024 --
November 22, 2024 --
November 08, 2024 --
August 29, 2024 --
August 09, 2024 --
May 15, 2024 --
May 10, 2024 --
Date Value
April 21, 2024 --
April 11, 2024 --
March 27, 2024 --
March 13, 2024 --
March 12, 2024 --
March 11, 2024 --
February 06, 2024 --
November 23, 2023 --
November 10, 2023 --
June 26, 2023 --
May 12, 2023 --
May 10, 2023 --
May 09, 2023 --
April 17, 2023 --
April 10, 2023 --
April 06, 2023 --
March 13, 2023 --
March 07, 2023 --
March 06, 2023 --
February 24, 2023 --
February 04, 2023 --

Revenue Estimates for Next Fiscal Year Range, Past 5 Years

View Revenue Estimates for Next Fiscal Year Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Next Fiscal Year Benchmarks

View Revenue Estimates for Next Fiscal Year Benchmarks
Start Trial
Q32 Bio, Inc. Upgrade
Beam Therapeutics, Inc. Upgrade
C4 Therapeutics, Inc. Upgrade
Cullinan Therapeutics, Inc. Upgrade
Arrowhead Pharmaceuticals, Inc. Upgrade

Revenue Estimates for Next Fiscal Year Related Metrics

EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade